Pharmacotherapy for end-stage coronary artery disease

Expert Opin Pharmacother. 2010 Feb;11(2):207-13. doi: 10.1517/14656560903439737.

Abstract

Importance of the field: Coronary artery disease remains the leading cause of mortality in the industrialized world. Despite advances in surgical and catheter-based interventions, a select number of patients remain with no options for invasive therapy. The goal of this review is to discuss the current status of pharmacotherapeutic interventions to treat end-stage coronary artery disease.

Areas covered in this review: Literature review on the topic of therapeutic angiogenesis from 1980 to 2009.

What the reader will gain: Insight into current therapeutic strategies employed to manage end-stage coronary artery disease.

Take home message: A promising approach focuses on augmenting the endogenous angiogenic response to chronic myocardial ischemia via the use of growth factors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Arteries
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / genetics
  • Coronary Artery Disease / physiopathology*
  • Genetic Therapy
  • Humans
  • Mice
  • Neovascularization, Pathologic / genetics*
  • Vascular Endothelial Growth Factor A / genetics*

Substances

  • Vascular Endothelial Growth Factor A